Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kitov Pharma Ltd (KTOV)

Kitov Pharma Ltd (KTOV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,573
  • Shares Outstanding, K 15,725
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -5,850 K
  • 60-Month Beta 2.37
  • Price/Sales 64.16
  • Price/Cash Flow N/A
  • Price/Book 1.17
Trade KTOV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.92 +6.24%
on 11/24/20
4.42 -5.66%
on 12/01/20
+0.11 (+2.71%)
since 11/20/20
3-Month
3.80 +9.76%
on 09/24/20
5.05 -17.43%
on 10/23/20
-0.28 (-6.29%)
since 09/21/20
52-Week
2.20 +89.55%
on 03/16/20
14.40 -71.04%
on 06/29/20
-3.23 (-43.65%)
since 12/20/19

Most Recent Stories

More News
Purple Biotech to Present at the B. Riley Oncology Investor Conference

Purple Biotech Ltd. ("Purple Biotech") (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the Purple...

PPBT : 4.95 (-1.98%)
KTOV : 4.17 (+2.21%)
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell

Virtual Bell-Ringing Ceremony in Celebration of Company's Recent Name Change to Purple Biotech

PPBT : 4.95 (-1.98%)
KTOV : 4.17 (+2.21%)
Kitov Announces Name Change to Purple Biotech Ltd.

New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies

KTOV : 4.17 (+2.21%)
Kitov Pharma to Participate in November Investor Conferences

Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that management will present...

KTOV : 4.17 (+2.21%)
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb

Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the company and Bristol...

KTOV : 4.17 (+2.21%)
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219

Patent covers NT219's combinations with multiple 2 and 3 generation EGFR inhibitors, including osimertinib (TAGRISSO(R))

KTOV : 4.17 (+2.21%)
New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference

Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance

KTOV : 4.17 (+2.21%)
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the first patient...

KTOV : 4.17 (+2.21%)
Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company's Lead Oncology Assets, CM24 and NT219

Kitov's patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries

KTOV : 4.17 (+2.21%)
Kitov Pharma Announces ADS Ratio Change

Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced today that the Company will...

KTOV : 4.17 (+2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kitov Pharmaceuticals Holdings Ltd. is a pharmaceutical company which focused on the development of therapeutic candidates. The company's product candidate consists of KIT-302, is formulated for treatment of pain caused by osteoarthritis and hypertension, which can be pre-existing or caused by the treatment...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 4.30
1st Resistance Point 4.24
Last Price 4.17
1st Support Level 4.06
2nd Support Level 3.94
3rd Support Level N/A

See More

52-Week High 14.40
Fibonacci 61.8% 9.74
Fibonacci 50% 8.30
Fibonacci 38.2% 6.86
Last Price 4.17
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar